Candel Therapeutics, Inc. Profile Avatar - Palmy Investing

Candel Therapeutics, Inc.

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase I…

Biotechnology
US, Needham [HQ]

Government Awards Analysis Beta

Obligations Over-Time

Awards
Obligations

Candel Therapeutics, Inc. has no obligation with a government/award agency.

Latest Obligations

Contracts
$ 0.0
IDVs
$ 0.0
Direct Payments
$ 0.0
Grants
$ 0.0
Loans
$ 0.0
Other Payments
$ 0.0
vs. Previous FY
Contracts
$ 0.0
IDVs
$ 0.0
Direct Payments
$ 0.0
Grants
$ 0.0
Loans
$ 0.0
Other Payments
$ 0.0

Spending By Type

Awards
Obligations

Candel Therapeutics, Inc. can't present spending by time.

Get PRO Today

With PRO you will unlock all insights related to government awards of Candel Therapeutics, Inc..

End of CADL's Analysis
CIK: 1841387 CUSIP: 137404109 ISIN: US1374041093 LEI: - UEI: -
Secondary Listings
CADL has no secondary listings inside our databases.